



New Advances in Clinical and Translational Breast Cancer Research

Guest Editors:

Dr. Carlos Martínez-Pérez

Institute of Genetics and Cancer,
Western General Hospital,
University of Edinburgh,
Edinburgh EH4 2XU, UK

Dr. Arran K. Turnbull

Institute of Genetics and Cancer,
Western General Hospital,
University of Edinburgh,
Edinburgh EH4 2XU, UK

Deadline for manuscript
submissions:

closed (31 August 2023)

Message from the Guest Editors

Despite significant improvements in breast cancer management and prognosis in recent decades, it remains the most common cancer and the leading cause of cancer-related death in women worldwide.

In addition to clinical studies, translational research—which utilises clinical samples and data for discovery and validation studies, and/or seeks to answer specific clinical questions—will be essential in addressing these needs and, crucially, bringing novel findings or emerging treatments closer to the clinic.

In this Special Issue, we will collect original research articles and reviews that report on or summarise the latest findings in clinical and translational breast cancer research. Such studies can lead to the identification or validation of novel biomarkers or potential therapeutic targets, the characterisation of the effects of emerging therapeutics or the development of predictive tools with clinical potential. Additionally, the study of clinical specimens can help shed light on the complexity of the disease, both identifying disease mechanisms or corroborating findings based on pre-clinical cancer models.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA
2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)